Mark I. Kemp

A novel selective and orally bioavailable <scp>N</scp> a <scp> _v </scp> 1.8 channel blocker, <scp>PF</scp> ‐01247324, attenuates nociception and sensory neuron excitability

C. Elizabeth Payne, Adam R. Brown, Jonathon W Theile et al. · British Journal of Pharmacology · 2015 · 101 citations · Full text

Medicine, Neurobiology, Pharmacology +14

Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s disease mouse model

Tracy-Shi Zhang Fang, Yu Sun, Andrew C. Pearce et al. · Nature Communications · 2023 · 91 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Subtype‐specific actions of <i>β</i>‐amyloid peptides on recombinant human neuronal nicotinic acetylcholine receptors (<i>α</i>7, <i>α</i>4<i>β</i>2, <i>α</i>3<i>β</i>4) expressed in <i>Xenopus laevis</i> oocytes

Luanda Pym, Mark I. Kemp, Valérie Raymond et al. · British Journal of Pharmacology · 2005 · 49 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

Modulation of the Partition Coefficient between Octanol and Buffer at pH 7.4 and p Ka to Achieve the Optimum Balance of Blood Clearance and Volume of Distribution for a Series of Tetrahydropyran Histamine Type 3 Receptor Antagonists

Tanya Hay, Rhys D.O. Jones, Kevin Beaumont et al. · Drug Metabolism and Disposition · 2009 · 46 citations

Medicine, Pharmacokinetics, Pharmacology +15

LY339434, a GluR5 kainate receptor agonist

Ben G. Small, J W Thomas, Mark I. Kemp et al. · Neuropharmacology · 1998 · 45 citations

Medicine, Neuroscience, Pharmacology +12